title: Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  To compare the efficacy, safety and compliance of repaglinide, administered either two or three times daily, regarding glycaemic control in patients with type 2 diabetes mellitus.
  
  
  METHODS
  Japanese adults with type 2 diabetes mellitus, who had been treated without sulphonylureas or glinides for >3 months, were randomly assigned to two groups to receive either 0.25 mg repaglinide, oral, twice daily (group A) or 0.25 mg repaglinide, oral, three times daily (group B). Glycosylated haemoglobin (HbA1c), glycoalbumin (GA) and 1,5-anhydroglucitol (1,5-AG) levels were measured at 0, 1, 2 and 3 months after treatment commenced.
  
  
  RESULTS
  Out of 43 patients who enrolled (group A, n = 22; group B, n = 21), 33 patients completed the trial (group A, n = 16; group B, n = 17). No significant between-group differences in HbA1c, GA, or 1,5-AG levels were seen at 1-3 months. No severe hypoglycaemic episodes or other adverse events were observed.
  
  
  CONCLUSIONS
  Minimal-dose repaglinide administered twice daily was similar in efficacy and safety to three-times-daily administration, in Japanese patients with type 2 diabetes mellitus. Administration of repaglinide twice daily could be an alternative regimen for patients who cannot take repaglinide three times daily.
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kamiyama
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan Department of Biostatistics and Epidemiology, Yokohama City University Hospital, Yokohama, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.affiliation: Nakajima Naika Clinic, Yokosuka, Japan.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nakajima
authors.affiliation: Nakajima Naika Clinic, Yokosuka, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Shinoda
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kamiko
authors.affiliation: Department of Biostatistics and Epidemiology, Yokohama City University Hospital, Yokohama, Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Taguri
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan terauchi@yokohama-cu.ac.jp.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D002219:Carbamates / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis*; D038321:Glycemic Index; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007564:Japan; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage*; D011379:Prognosis
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010880:Piperidines; C072379:repaglinide
keywords: Repaglinide; drug adherence; type 2 diabetes